The 4′-hydroxyl group of resveratrol is functionally important for direct activation of PPARα

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Takizawa, Yoshie ^a   Nakata, Rieko ^a   Fukuhara, Kiyoshi ^b   Yamashita, Hiroshi ^c   Kubodera, Hideo ^c   Inoue, Hiroyasu ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYSTILBENE; 4 PHENYLAZOPHENOL; APIGENIN; AZOBENZENE; FLAVONE; FORSKOLIN; KAEMPFEROL; LUTEOLIN; NOBILETIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOL DERIVATIVE; PHOSPHODIESTERASE; PICEATANNOL; PIRINIXIC ACID; POLYPHENOL; PTEROSTILBENE; RESVERATROL; ROLIPRAM; STILBENE DERIVATIVE; TANGERETIN; UNCLASSIFIED DRUG; HYDROXIDE; HYDROXIDE ION; PHOSPHODIESTERASE INHIBITOR; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; IC50; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; GENE INACTIVATION; METABOLISM; PROTEIN CONFORMATION;

MUS; VITACEAE;

ANIMALS; GENE KNOCKOUT TECHNIQUES; HYDROXIDES; MALE; MICE; MOLECULAR DOCKING SIMULATION; PHOSPHODIESTERASE INHIBITORS; PPAR ALPHA; PROTEIN CONFORMATION; SIRTUIN 1; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925799245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120865     Document Type: Article

References (30)

1. Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol. 1976; 9: 77-86.
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275: 218-220. PMID: 8985016
3. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998; 273: 21875-21882. PMID: 9705326
4. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice. Neurosci Lett. 2003; 352: 203-206. PMID: 14625020
5. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425: 191-196. PMID: 12939617
6. Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49: 405-430. PMID: 15832402
7. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5: 493-506. PMID: 16732220
8. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. J Nutr. 1935; 10: 63-79.
9. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005; 280:17038-17045. PMID: 15684413
10. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010; 285: 8340-8351. doi: 10.1074/jbc.M109.088682 PMID: 20061378
11. Park SJ. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012; 148: 421-433. doi: 10.1016/j.cell.2012.01.017 PMID: 22304913
12. Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull. 2012; 35: 273-270. PMID: 22382311
13. Tsukamoto T, Nakata R, Tamura E, Kosuge Y, Kariya A, Katsukawa M, et al. Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo. Nutr Metab. 2010; 7: 46.
14. Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, et al. Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J Biol Chem. 2004; 279: 46204-46212. PMID: 15302862
15. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835-839. PMID: 8521507
16. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006; 58: 726-741. PMID: 17132851
17. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999; 3: 397-403. PMID: 10198642
18. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14- prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 1995; 83: 803-812. PMID: 8521497
19. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995; 83: 813-819. PMID: 8521498
20. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem. 2000; 275: 28028-28032. PMID: 10827178
21. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T. Transcriptional and Posttranscriptional Regulation of Cyclooxygenase-2 Expression by Fluid Shear Stress in Vascular Endothelial Cells. Arterioscler Thromb Vasc Biol. 2002; 22: 1415-1420. PMID: 12231559
22. Thakkar K, Geahlen RL, Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem. 1993; 36: 2950-2955. PMID: 8411012
23. Hotta M, Nakata R, Katsukawa M, Hori K, Takahashi S, Inoue H. Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression. J Lipid Res. 2010; 51: 132-139. doi: 10. 1194/jlr.M900255-JLR200 PMID: 19578162
24. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997; 267: 727-748. PMID: 9126849
25. Kuhn B, Kollman PA. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J Med Chem. 2000; 43: 3786-3791. PMID: 11020294
26. Kleppisch T. Phosphodiesterases in the central nervous system. Handb Exp Pharmacol. 2009; 191: 71-92. doi: 10.1007/978-3-540-68964-5-5 PMID: 19089326
27. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator activated receptors. Proc Natl Acad Sci USA. 2001; 98: 13919-13924. PMID: 11698662
28. Calleri E, Pochetti G, Dossou KS, Laghezza A, Montanari R, Capelli D, et al. Resveratrol and its metabolites bind to PPARs. ChemBioChem. 2014; 15: 1154-1160. doi: 10.1002/cbic.201300754 PMID: 24796862
29. Zhao P, Chen SK, Cai YH, Lu X, Li Z, Cheng YK, et al. The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay. Biochim Biophys Acta. 2013; 1834: 2089-2096. doi: 10.1016/j.bbapap.2013.07.004 PMID: 23871879
30. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9: 327-338. doi: 10.1016/j.cmet.2009.02.006 PMID: 19356714